Oculis Reports the Completion of Patient Enrolment in P-III Trial (OPTIMIZE) of OCS-01 for the Treatment of Inflammation and Pain
March 17, 2023
Oculis to go Public via EBAC SPAC Merger for ~$220M
October 19, 2022
Oculis Reports Results of OCS-01 in P-II (DX-211) Study for the Treatment of Diabetic Macular Edema
September 6, 2022
Oculis Published P-II Study Results of Licaminlimab (OCS-02) for the Treatment of Severe Dry Eye Disease in Clinical Ophthalmology
August 24, 2022
Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Followi...
June 29, 2022
Oculis Entered into a License Agreement with Accure Therapeutics to Develop and Commercialize ACT-01 for Acute Optic Neuritis and...
March 3, 2022
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.